431 related articles for article (PubMed ID: 24778075)
1. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer.
Park MS; Lee SM
Anticancer Res; 2014 May; 34(5):2551-4. PubMed ID: 24778075
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
[TBL] [Abstract][Full Text] [Related]
3. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
Jo JE; Kim JY; Lee SH; Kim S; Kang T
Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
[TBL] [Abstract][Full Text] [Related]
4. Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer.
Lee JY; Kim HJ; Yim SH; Shin DS; Yu JH; Ju DY; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2013 Oct; 62(4):227-33. PubMed ID: 24162710
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer.
Corvera CU; Blumgart LH; Akhurst T; DeMatteo RP; D'Angelica M; Fong Y; Jarnagin WR
J Am Coll Surg; 2008 Jan; 206(1):57-65. PubMed ID: 18155569
[TBL] [Abstract][Full Text] [Related]
6. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Performance and Prognostic Relevance of FDG Positron Emission Tomography/Computed Tomography for Patients with Extrahepatic Cholangiocarcinoma.
Kim NH; Lee SR; Kim YH; Kim HJ
Korean J Radiol; 2020 Dec; 21(12):1355-1366. PubMed ID: 32767862
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of Prognostic Impact of Tumor SUVmax by
Yoh T; Seo S; Morino K; Fuji H; Ikeno Y; Ishii T; Taura K; Nakamoto Y; Higashi T; Kaido T; Uemoto S
World J Surg; 2019 May; 43(5):1323-1331. PubMed ID: 30680501
[TBL] [Abstract][Full Text] [Related]
9. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma.
Pak K; Kim SJ; Kim IJ; Kim DU; Kim K; Kim H; Kim SJ
Nuklearmedizin; 2014; 53(2):26-31. PubMed ID: 24305850
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between TNM staging of primary cholangiocarcinoma and the maximum standard uptake value of (18)F-2-deoxy-D-glucose positron emission tomography with computerized tomography].
Wang ZF; Lan XL; Xiao YR; Liu JP; Ji JS
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(39):3104-3107. PubMed ID: 29081157
[No Abstract] [Full Text] [Related]
12. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Mori A; Doi R; Ikai I; Uemoto S
Surgery; 2008 Jun; 143(6):769-77. PubMed ID: 18549893
[TBL] [Abstract][Full Text] [Related]
14. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma.
Kim YJ; Yun M; Lee WJ; Kim KS; Lee JD
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1467-72. PubMed ID: 14579085
[TBL] [Abstract][Full Text] [Related]
17. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
Kim JY; Kim MH; Lee TY; Hwang CY; Kim JS; Yun SC; Lee SS; Seo DW; Lee SK
Am J Gastroenterol; 2008 May; 103(5):1145-51. PubMed ID: 18177454
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
19. Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma.
Park TG; Yu YD; Park BJ; Cheon GJ; Oh SY; Kim DS; Choe JG
Clin Nucl Med; 2014 Jan; 39(1):1-7. PubMed ID: 24335565
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study.
Hwang JP; Moon JH; Kim HK; Lee MH; Lim CH; Park SB; Yoon JK; Park JM
Medicine (Baltimore); 2021 May; 100(21):e26015. PubMed ID: 34032720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
